Professor, Pathology, University Massachusetts Medical School
Pathology
Dr. Bruce A. Woda, MD
|
|
Give Review
Doctor Bruce A. Woda, MD works in the field of Pathology. He researched medicine at State University of New York Downstate Medical Center College of Medicine. Bruce A. Woda is a published physician as well. He has 52 publications published. The latest was: MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. He is registered with Medicare.
Publications
- Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohist...
- Oncofetal Protein IMP3, a New Cancer Biomarker.
- MYC Protein Expression Is Detected in Plasma Cell Myeloma but Not in Monoclonal Gammopathy of Undetermined Significance (MGUS).
- Five important advances in hematopathology.
- Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors.
- Advances in understanding the pathogenesis of HLH.
- Transformation of follicular lymphoma to epstein-barr virus-related hodgkin-like lymphoma.
- Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML).
- Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.
- Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations.
- IMP3, a New Biomarker to Predict Progression of Cervical Intraepithelial Neoplasia Into Invasive Cancer.
- The Oncofetal Protein IMP3: A Novel Molecular Marker to Predict Aggressive Meningioma.
- IMP2 Expression Distinguishes Endometrioid From Serous Endometrial Adenocarcinomas.
- Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
- Anaplastic lymphoma kinase-positive large B-cell lymphoma with complex karyotype and novel ALK gene rearrangements.
- High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.
- Infection with viruses from several families triggers autoimmune diabetes in LEW*1WR1 rats: prevention of diabetes by maternal immunization.
- Chronic basophilic leukemia: a rare form of chronic myeloproliferative neoplasm.
- Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfal...
- Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal ...
- Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
- Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas.
- Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) mice.
- Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma.
- Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas.
- Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma.
- Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
- IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
- A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
- Mosaic tetraploidy and transient GFI1 mutation in a patient with severe chronic neutropenia.
- Hypersensitivity pneumonitis: an immunopathology review.
- Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
- IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
- Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
- LEW.1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation.
- KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
- Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays.
- Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.
- Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
- Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
- Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
- P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens.
- Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
- Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
- Intercellular adhesion molecules (ICAM-1, VCAM-1, and LFA-1) in adenocarcinoma of lung. Technical aspects.
- P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
- Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
- Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer.
- Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms.
- Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma.
- MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
Schools
Suny Downstate Medical Center
Columbia Presby
City Hope
Doctors Specialties
- Anatomic Pathology
- Pathology
Accepted Insurances
- Blue Card PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Commercial Insurance Company
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
City of Hope National Medical Center -
New York Presbyterian Hospital - Columbia Campus -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
UMass Memorial Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770568354 |
| Last Name Of The Provider | WODA |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Otto Walter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaofei Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francoise Truong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas C. King, MD |
|
|
Dr. Nicholas J. Barnard, MD |
|
|
Dr. Benjamin M. Terry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuxin Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashraf Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth L. Rock, MD |
|
|
Dr. Leslie A. Dowd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Agnes B. Russfield, MD |